Drug Profile
Huperzine A - Shandong Luye Pharmaceuticals
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Shandong Luye Pharmaceutical
- Class Alkaloids; Antiepileptic drugs; Neuroprotectants; Nootropics; Sesquiterpenes; Small molecules
- Mechanism of Action Acetylcholinesterase inhibitors; Amyloid beta-protein inhibitors; Antioxidants; NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 17 Jun 2015 No recent reports on development identified - Phase-II/III for Alzheimer's disease in China (PO)